Business Context and Reporting Period
Company: American Shared Hospital Services (ASHS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1998
ASHS historically provided diagnostic imaging services (MRI, CT, Ultrasound, Nuclear Medicine, Cardiac Catheterization) to approximately 190 customers. In November 1998, the Company sold this diagnostic imaging business to affiliates of Alliance Imaging, Inc. for $13.55 million in cash and the assumption of approximately $27.1 million in liabilities. Following the sale, the Company's primary business is the provision of stereotactic radiosurgery services via the Leksell Gamma Knife to five medical centers in three states, operated through an 81% interest in GK Financing, LLC.
Key Financial Metrics
| Metric (in thousands) | 1998 | 1997 |
|---|---|---|
| Medical Services Revenues | $35,162 | $37,172 |
| Net Income | $20,051 | $1,522 |
| Earnings Per Share (Basic) | $4.23 | $0.32 |
| Operating Cash Flow | $7,731 | $7,271 |
| Cash and Cash Equivalents (End of Period) | $11,114 | $17 |
| Working Capital | $9,088 | $(8,039) |
| Total Debt (Current + Long-Term) | $10,665 | $16,720 |
| Shareholders' Equity | $11,096 | $(8,953) |
Note: 1998 Net Income includes a one-time gain of $20,478,000 from the sale of the diagnostic imaging product line. Excluding this gain, operating income was approximately $1,073,000.
Material Changes vs. Prior Period
- Revenue Decline: Total medical services revenues decreased 5.4% to $35.2 million, primarily due to the November 1998 sale of the diagnostic imaging business, which previously accounted for 88% of revenues.
- Profitability Surge: Net income increased 1,217% to $20.1 million, driven almost entirely by the $20.5 million gain on the disposal of the product line. Operating margins improved on a continuing basis due to reduced overhead.
- Liquidity Transformation: Cash and cash equivalents increased from $17,000 in 1997 to $11.1 million in 1998. The sale eliminated a net capital deficiency of $8.95 million, resulting in positive shareholders' equity of $11.1 million.
- Debt Reduction: Total debt decreased by approximately $6.1 million as the purchaser assumed $27.1 million of the Company's liabilities.
- Gamma Knife Growth: Revenues from the Gamma Knife segment increased 74% to $4.2 million (11.8% of total revenue) due to the addition of two new units in 1998.
Outlook, Risks, and Management Commentary
Outlook and Strategy: Management states that the 1998 results are not indicative of future performance due to the one-time sale. The Company intends to invest its cash reserves in overnight repurchase agreements and commercial paper. Future growth depends on expanding the Gamma Knife business, with four additional sites under development expected to become operational in 1999.
Key Risks:
- Reimbursement Rates: Significant risk of declining reimbursement rates from Medicare and third-party payors, particularly under proposed Ambulatory Product Classifications (APC) which may categorize radiosurgery with conventional radiation therapy, reducing payments.
- Competition: Competition from conventional neurosurgery, modified linear accelerators, and other Gamma Knife providers. The Company does not have an exclusive relationship with the manufacturer, Elekta.
- Capital Intensity: Each Gamma Knife unit requires a substantial investment (approx. $2.9 million). Recovery of costs is not guaranteed.
- Listing Status: The Company's stock was at risk of delisting from the American Stock Exchange and Pacific Exchange due to net capital deficiency and low share price, though management believes the sale resolves these criteria.
Unusual Items: The $20.5 million gain on sale of product line is a non-recurring item. The Company also accrued $995,000 in exit costs related to the sale.
Investor Verification Checklist
- Continuing Operations Viability: Verify the profitability of the Gamma Knife segment excluding the one-time sale gain to assess sustainable earnings power.
- Reimbursement Exposure: Confirm the impact of pending Medicare APC regulations on the Company's shared-revenue contracts.
- Debt Covenants: Review the debt-to-equity covenants for GK Financing, LLC, which may require additional capital contributions to fund new unit deployments.
- Stock Listing Status: Confirm the final ruling by the American Stock Exchange and Pacific Exchange regarding continued listing.
- Customer Concentration: Note that while no single customer exceeded 10% of total revenue, each of the five Gamma Knife customers accounted for more than 10% of Gamma Knife segment revenue.